Azenta, Inc. (AZTA) stock analysis

Healthcare · Medical Instruments & Supplies

From the 10-K filed 2025-12-04

How it makes money

It grew revenue by 4% in 2025 by providing automated cold storage and genomic services to approximately 14,000 customers.

It manages a "cold chain of custody" for biological samples, providing automated storage systems that hold up to 20 million samples at temperatures ranging from ambient to -80°C.

Revenue is driven by a mix of high-margin Sample Repository Services and Multiomics lab requests, such as gene sequencing and synthesis, for approximately 14,000 global partners. It targets pharmaceutical and biotechnology firms that outsource logistics and analysis for their biological assets.

What protects it: the moat

It maintains 103 issued U.S. patents and proprietary storage systems with the industry's highest throughput for retrieval at temperatures down to -80°C.

Management asserts its automated stores provide the highest throughput of sample retrieval in the industry for temperatures as low as -80°C. This technical advantage creates high switching costs for pharmaceutical customers who rely on the company's integrated informatics and controlled-rate thawing devices to maintain sample integrity.

Protection is bolstered by 103 U.S. patents and 545 foreign patents, alongside proprietary trade secrets for cryogenics and automation technology that were originally developed for the semiconductor industry.

What growth costs

The company maintains 14 global laboratories to provide genomic services and develops specialized protocols for analyzing adeno-associated virus vectors.

It operates a network of 14 laboratories across the United States, China, United Kingdom, Japan, and Germany to support its Multiomics segment and high-throughput sequencing activities.

Reinvestment focuses on expanding the portfolio to include proteomics and specialized analysis for adeno-associated virus, a critical vector in cell and gene therapy. The company historically uses cash from its $2.9 billion semiconductor business sale to fund these life sciences acquisitions and laboratory expansions.

What could damage it

Loss of GLP accreditation or damage to customer biological materials in its automated stores could trigger liability claims and contract terminations.

Because it stores millions of unique, often irreplaceable biological samples for research, any mechanical failure or breach of the cold chain creates immediate financial liability and reputational harm.

Additionally, the business depends on maintaining Good Laboratory Practice (GLP) accreditation. Losing these certifications would lead to the loss of customer contracts and regulatory penalties, as these standards are required for the regulated analysis services that drive Multiomics revenue.

About Azenta, Inc.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Other companies in Medical Instruments & Supplies